Involvement of NEK2 and its interaction with NDC80 and CEP250 in hepatocellular carcinoma

[1]  Lei Kong,et al.  CGPS: A machine learning-based approach integrating multiple gene set analysis tools for better prioritization of biologically relevant pathways. , 2018, Journal of genetics and genomics = Yi chuan xue bao.

[2]  Hequan Yao,et al.  Novel 2-phenyloxypyrimidine derivative induces apoptosis and autophagy via inhibiting PI3K pathway and activating MAPK/ERK signaling in hepatocellular carcinoma cells , 2018, Scientific Reports.

[3]  Piao Guo,et al.  HCC-derived exosomes elicit HCC progression and recurrence by epithelial-mesenchymal transition through MAPK/ERK signalling pathway , 2018, Cell Death & Disease.

[4]  S. Shen,et al.  NEK2 promotes hepatocellular carcinoma migration and invasion through modulation of the epithelial-mesenchymal transition , 2018, Oncology reports.

[5]  Thawfeek M. Varusai,et al.  The Reactome Pathway Knowledgebase , 2017, Nucleic Acids Res..

[6]  C. la Vecchia,et al.  Global trends and predictions in hepatocellular carcinoma mortality. , 2017, Journal of hepatology.

[7]  Chad J. Creighton,et al.  UALCAN: A Portal for Facilitating Tumor Subgroup Gene Expression and Survival Analyses , 2017, Neoplasia.

[8]  J. Shao,et al.  Effect of NDC80 in human hepatocellular carcinoma , 2017, World journal of gastroenterology.

[9]  M. Pedrosa,et al.  Identifying barriers to hepatocellular carcinoma surveillance in a national sample of patients with cirrhosis , 2017, Hepatology.

[10]  Yingfei Li,et al.  NIMA-related kinase 2 regulates hepatocellular carcinoma cell growth and proliferation , 2017, Oncology letters.

[11]  Jiagui Chen,et al.  NEK2 serves as a prognostic biomarker for hepatocellular carcinoma , 2017, International journal of oncology.

[12]  Manyi Yang,et al.  Increased NEK2 in hepatocellular carcinoma promotes cancer progression and drug resistance by promoting PP1/Akt and Wnt activation. , 2016, Oncology reports.

[13]  Allison P. Heath,et al.  Toward a Shared Vision for Cancer Genomic Data. , 2016, The New England journal of medicine.

[14]  M. Nagino,et al.  Nek2 siRNA therapy using a portal venous port–catheter system for liver metastasis in pancreatic cancer , 2016, Cancer science.

[15]  Yang Yang,et al.  ShRNA-mediated silencing of the Ndc80 gene suppress cell proliferation and affected hepatitis B virus-related hepatocellular carcinoma. , 2016, Clinics and research in hepatology and gastroenterology.

[16]  Peng Zhang,et al.  Effect of silencing NEK2 on biological behaviors of HepG2 in human hepatoma cells and MAPK signal pathway , 2016, Tumor Biology.

[17]  L. Stein,et al.  The Reactome pathway Knowledgebase , 2015, Nucleic Acids Res..

[18]  A. Fry,et al.  Overexpression of the Nek2 kinase in colorectal cancer correlates with beta‐catenin relocalization and shortened cancer‐specific survival , 2014, Journal of surgical oncology.

[19]  Davide Heller,et al.  STRING v10: protein–protein interaction networks, integrated over the tree of life , 2014, Nucleic Acids Res..

[20]  A. Fry,et al.  Multisite phosphorylation of C-Nap1 releases it from Cep135 to trigger centrosome disjunction , 2014, Journal of Cell Science.

[21]  Zhong-yu Wang,et al.  Abnormal expression of Nek2 in pancreatic ductal adenocarcinoma: a novel marker for prognosis. , 2014, International journal of clinical and experimental pathology.

[22]  Tianhong Zhang,et al.  GeneSense: a new approach for human gene annotation integrated with protein-protein interaction networks , 2014, Scientific Reports.

[23]  Yi Lu,et al.  Upregulation of NEK2 is associated with drug resistance in ovarian cancer. , 2014, Oncology reports.

[24]  Rong Wang,et al.  PPP1R42, a PP1 binding protein, regulates centrosome dynamics in ARPE‐19 cells , 2013, Biology of the cell.

[25]  Benjamin E. Gross,et al.  Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal , 2013, Science Signaling.

[26]  T. Ørntoft,et al.  The splicing factor SRSF6 is amplified and is an oncoprotein in lung and colon cancers , 2013, The Journal of pathology.

[27]  R. Purohit,et al.  CEP proteins: the knights of centrosome dynasty , 2013, Protoplasma.

[28]  H. Lehrach,et al.  LGALS3BP regulates centriole biogenesis and centrosome hypertrophy in cancer cells , 2013, Nature Communications.

[29]  F. Zhan,et al.  NEK2 induces drug resistance mainly through activation of efflux drug pumps and is associated with poor prognosis in myeloma and other cancers. , 2013, Cancer cell.

[30]  Peter Dockery,et al.  C-NAP1 and rootletin restrain DNA damage-induced centriole splitting and facilitate ciliogenesis , 2012, Cell cycle.

[31]  A. Vinayagam,et al.  A Directed Protein Interaction Network for Investigating Intracellular Signal Transduction , 2011, Science Signaling.

[32]  Stephanie Roessler,et al.  A unique metastasis gene signature enables prediction of tumor relapse in early-stage hepatocellular carcinoma patients. , 2010, Cancer research.

[33]  M. Nagino,et al.  Novel combination treatment for colorectal cancer using Nek2 siRNA and cisplatin , 2010, Cancer science.

[34]  R. Fisher,et al.  Genes Involved in Viral Carcinogenesis and Tumor Initiation in Hepatitis C Virus-Induced Hepatocellular Carcinoma , 2009, Molecular medicine.

[35]  I. Ng,et al.  Role of a novel splice variant of mitotic arrest deficient 1 (MAD1), MAD1beta, in mitotic checkpoint control in liver cancer. , 2008, Cancer research.

[36]  Phang-lang Chen,et al.  Small molecule targeting the Hec1/Nek2 mitotic pathway suppresses tumor cell growth in culture and in animal. , 2008, Cancer research.

[37]  E. F. da Cruz e Silva,et al.  Alternative Splicing Controls Nuclear Translocation of the Cell Cycle-regulated Nek2 Kinase* , 2007, Journal of Biological Chemistry.

[38]  V. Mazzaferro,et al.  Genome‐wide molecular profiles of HCV‐induced dysplasia and hepatocellular carcinoma , 2007, Hepatology.

[39]  Yangtong Lou,et al.  Nek2A specifies the centrosomal localization of Erk2. , 2004, Biochemical and biophysical research communications.

[40]  K. Noguchi,et al.  Nucleolar Nek11 Is a Novel Target of Nek2A in G1/S-arrested Cells* , 2004, Journal of Biological Chemistry.

[41]  Xuebiao Yao,et al.  NEK2A Interacts with MAD1 and Possibly Functions as a Novel Integrator of the Spindle Checkpoint Signaling* , 2004, Journal of Biological Chemistry.

[42]  D. Riley,et al.  Phosphorylation of the Mitotic Regulator Protein Hec1 by Nek2 Kinase Is Essential for Faithful Chromosome Segregation* , 2002, The Journal of Biological Chemistry.

[43]  D. Brautigan,et al.  Inhibitor-2 Regulates Protein Phosphatase-1 Complexed with NimA-related Kinase to Induce Centrosome Separation* , 2002, The Journal of Biological Chemistry.

[44]  A. Fry.  The Nek2 protein kinase: a novel regulator of centrosome structure , 2002, Oncogene.

[45]  D. Botstein,et al.  Gene expression patterns in human liver cancers. , 2002, Molecular biology of the cell.

[46]  R. Gray.  Modeling Survival Data: Extending the Cox Model , 2002 .

[47]  P. Meraldi,et al.  Centrosome cohesion is regulated by a balance of kinase and phosphatase activities. , 2001, Journal of cell science.

[48]  Carl W. Miller,et al.  Mutations in the mitotic check point gene, MAD1L1, in human cancers , 2001, Oncogene.

[49]  P. Cohen,et al.  NIMA-related kinase 2 (Nek2), a cell-cycle-regulated protein kinase localized to centrosomes, is complexed to protein phosphatase 1. , 2000, The Biochemical journal.

[50]  P. Meraldi,et al.  C-Nap1, a Novel Centrosomal Coiled-Coil Protein and Candidate Substrate of the Cell Cycle–regulated Protein Kinase Nek2 , 1998, The Journal of cell biology.

[51]  Baoying Hu,et al.  Downregulation of Nedd4L predicts poor prognosis, promotes tumor growth and inhibits MAPK/ERK signal pathway in hepatocellular carcinoma. , 2018, Biochemical and biophysical research communications.

[52]  Xianglei He,et al.  Low expression of NEK2 is associated with hepatocellular carcinoma progression and poor prognosis. , 2017, Cancer biomarkers : section A of Disease markers.

[53]  A. Dreher.  Modeling Survival Data Extending The Cox Model , 2016 .

[54]  H. Saavedra,et al.  Nek2 and Plk4: prognostic markers, drivers of breast tumorigenesis and drug resistance. , 2014, Frontiers in bioscience.

[55]  Brad T. Sherman,et al.  Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources , 2008, Nature Protocols.

[56]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..

[57]  P. Grambsch,et al.  Estimating the Survival and Hazard Functions , 2000 .